Get the Stockscreener App
32.57
1.40%
0.45
After Hours:
32.47
-0.10
-0.31%
Cue Biopharma Inc stock is traded at $32.57, with a volume of 232.93K.
It is up +1.40% in the last 24 hours and up +28.28% over the past month.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
See More
Previous Close:
$32.12
Open:
$32.91
24h Volume:
232.93K
Relative Volume:
0.48
Market Cap:
$136.81M
Revenue:
$32.73M
Net Income/Loss:
$-19.52M
P/E Ratio:
-5.8924
EPS:
-5.5275
Net Cash Flow:
$-24.61M
1W Performance:
+5.23%
1M Performance:
+28.28%
6M Performance:
+177.95%
1Y Performance:
+22.97%
1-Day Range:
$31.14
$34.37
1-Week Range:
$29.93
$35.57
52-Week Range:
$4.971
$45.50
Cue Biopharma Inc Stock (CUE) Company Profile
Name
Cue Biopharma Inc
Sector
Industry
Phone
617-949-2680
Address
40 GUEST STREET, BOSTON, MA
Compare CUE vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
32.57 | 134.92M | 32.73M | -19.52M | -24.61M | -5.5275 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-24 | Initiated | Jefferies | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Nov-21-22 | Initiated | Piper Sandler | Overweight |
| Jan-13-22 | Initiated | H.C. Wainwright | Buy |
| Jan-03-22 | Initiated | Craig Hallum | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Apr-09-20 | Initiated | Stifel | Buy |
| Jan-28-20 | Initiated | BTIG Research | Buy |
| Jan-22-20 | Initiated | JMP Securities | Mkt Outperform |
View All
Cue Biopharma Inc Stock (CUE) Latest News
CUE|Cue Biopharma Inc|Price:32.120|Chg%:-0.970 - TradingKey
Cue Biopharma Inc (CUE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Enterprise value to EBITDA forward of Cue Biopharma, Inc. – NASDAQ:CUE - TradingView
Cue Biopharma Inc (CUE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CUE Stock Jumps Over 100% After Hours — What’s Driving The Rally? - Stocktwits
Cue Biopharma Inc (CUE) Income Statement - TradingKey
TradingKey - TradingKey
CUE Stock On Track For Best Day In History — Why Is Retail Optimistic? - Stocktwits
Cue Biopharma, Inc. Revenue Breakdown – NASDAQ:CUE - TradingView
Cue Biopharma Inc (CUE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Enterprise value to EBITDA forward of Cue Biopharma, Inc. – DUS:1UC0 - TradingView
Cue Biopharma (CUE) Stock Forecast & Analyst Ratings - Moomoo
Cue Biopharma, Inc. announced that it has received $49.999926 million in funding from Cormorant Asset Management, LP, Threadneedle Asset Management Limited - marketscreener.com
Cue Biopharma (CUE) completes $49,999,927 Reg D Rule 506(b) raise - Stock Titan
ETFs Investing in Cue Biopharma, Inc. Stocks - TradingView
Cue Biopharma (CUE) Q2 2024 earnings summary - Quartr
Form 4 Cue Biopharma For: 15 July By Investing.com - Investing.com Nigeria
Cue Biopharma (CUE) awards RSUs and stock options to CMO Borie - Stock Titan
Cue Biopharma (NASDAQ: CUE) CMO Dominique Borie files initial Form 3 - Stock Titan
Cue Biopharma appoints CMO - The Pharma Letter
Cue Biopharma (CUE) Edges Higher Amid Tight Trading RangeSingle Stock ETF - dars.gov.et
Cue Biopharma names Dominic Borie as CMO and head of R&D - MSN
Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight - GlobeNewswire Inc.
Cue Biopharma names Dominic Borie as chief medical officer By Investing.com - Investing.com Australia
Cue Biopharma names Dominic Borie as chief medical officer - Investing.com
Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development - The Manila Times
Biotech Stocks At 52-Week Highs: AMWL, CUE, ICCC, SRRK, FTH - RTTNews
Immunology veteran Dominic Borie to steer Cue Biopharma’s drug pipeline - Stock Titan
Enterprise value to EBIT forward of Cue Biopharma, Inc. – MUN:1UC0 - TradingView
Price to earnings forward of Cue Biopharma, Inc. – MUN:1UC0 - TradingView
Enterprise value to revenue forward of Cue Biopharma, Inc. – MUN:1UC0 - TradingView
Form 4 Cue Biopharma For: 10 July By Investing.com - Investing.com India
Cue Biopharma | 4: Statement of changes in beneficial ownership of securities-Director Garzone Pamela - Moomoo
Cue Biopharma (CUE) awards 21,800 time-vested RSUs to director Garzone - Stock Titan
Cue Biopharma | 4: Statement of changes in beneficial ownership of securities-Director Camardo Daniel A. - Moomoo
Cue Biopharma (CUE) awards 21,800 restricted stock units to board director - Stock Titan
Cue Biopharma (CUE) director Sarraf Pasha receives 21,800 RSU equity award - Stock Titan
Cue Biopharma | 4: Statement of changes in beneficial ownership of securities-Director Meehan Viola Mong - Moomoo
Cue Biopharma | 4: Statement of changes in beneficial ownership of securities-Officer Meluzio Michael Vincent - Moomoo
Cue Biopharma (CUE) awards 40,942 RSUs and 40,942 PSUs to accounting chief - Stock Titan
Cue Biopharma (CUE) awards 109,178-share RSU and PSU package to legal chief - Stock Titan
Cue Biopharma (CUE) CEO Shao-Lee Lin awarded 327,537-share RSU and PSU package - Stock Titan
Cue Biopharma Announces $50 Million Private Placement - TipRanks
Cue Biopharma Raises ~$50 Million in Private Placement With Cormorant, Columbia Threadneedle - TradingView
Cue Biopharma (Nasdaq: CUE) secures $50M private placement and grants over 1M RSUs - Stock Titan
Cue: The Market Is Paying $86M For A Drug It Doesn't Own (NASDAQ:CUE) - Seeking Alpha
Cue Biopharma Shares Rise on $50 Million Private Placement Pricing - Moomoo
Cue Biopharma Inc Stock (CUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):